1
|
Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, Krawczyk K, Stork M, Pour L, Usnarska-Zubkiewicz L, Potoczek S, Hus I, Davila Valls J, Hari P, Chhabra S, Gentile M, Mikala G, Varga G, Chim CS, Fiala M, Vij R, Schutz N, Rodzaj M, Porowska A, Vesole DH, Druzd-Sitek A, Walewski J, Nooka AK. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma 2020; 61:2868-2875. [DOI: 10.1080/10428194.2020.1788014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Artur Jurczyszyn
- Department of Hematology, Jagiellonian University Medical College, Cracow, Poland
| | - Anna Waszczuk-Gajda
- Department of Hematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland
| | - Jorge J. Castillo
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Katarzyna Krawczyk
- Department of Hematology, Jagiellonian University Medical College, Cracow, Poland
| | - Martin Stork
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - Ludek Pour
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - Lidia Usnarska-Zubkiewicz
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
| | - Stanisław Potoczek
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
| | - Iwona Hus
- Medical University of Lublin, Lublin Poland
| | | | - Parameswaran Hari
- Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Saurabh Chhabra
- Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | | | - Gabor Mikala
- Department of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute of Hematology and Infectology, Budapest, Hungary
| | - Gergely Varga
- 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
| | - Chor Sang Chim
- Division of Hematology and Medical Oncology, Queen Mary Hospital, Hong Kong, China
| | - Mark Fiala
- Washington University School of Medicine, St. Louis, MS, USA
| | - Ravi Vij
- Washington University School of Medicine, St. Louis, MS, USA
| | - Natalia Schutz
- Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Marek Rodzaj
- Department of Hematology, Regional Specialistic Hospital, Cracow, Poland
| | - Agnieszka Porowska
- Department of Oncology and Haematology, Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland
| | - David H. Vesole
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
| | | | - Jan Walewski
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | - Ajay K. Nooka
- School of Medicine, Emory University, Atlanta, GA, USA
| |
Collapse
|
2
|
Helbig G, Lewandowski K, Świderska A, Rodzaj M, Seferyńska I, Gajkowska-Kulik J. Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group. Pol Arch Intern Med 2020; 130:255-257. [PMID: 32125294 DOI: 10.20452/pamw.15224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Grzegorz Helbig
- Department of Hematology and Bone Marrow Transplantation, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
| | - Krzysztof Lewandowski
- Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznań, Poland
| | - Alina Świderska
- Department of Hematology, Regional Hospital, Zielona Góra, Poland
| | - Marek Rodzaj
- Department of Hematology, Rydygier Hospital, Kraków, Poland
| | - Ilona Seferyńska
- Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | | |
Collapse
|
3
|
Hus I, Mańko J, Jawniak D, Jurczyszyn A, Charliński G, Poniewierska-Jasak K, Usnarska-Zubkiewicz L, Sawicki M, Druzd-Sitek A, Świderska A, Kopińska A, Grząśko N, Raźny M, Wędłowska A, Perzyński A, Gałązka A, Dytfeld D, Kubicki T, Rodzaj M, Waszczuk-Gajda A, Drozd-Sokołowska J, Pogłódek B, Pasternak A, Długosz-Danecka M, Szymczyk A, Dmoszyńska A. High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. Oncol Lett 2019; 18:5811-5820. [PMID: 31788054 PMCID: PMC6865789 DOI: 10.3892/ol.2019.10929] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2019] [Accepted: 08/07/2019] [Indexed: 11/28/2022] Open
Abstract
The present retrospective analysis evaluated the efficacy and safety of the VTD (bortezomib, thalidomide, dexamethasone) regimen in 205 newly-diagnosed patients with multiple myeloma (MM) eligible for high dose therapy and autologous stem cell transplantation (HDT/ASCT) in routine clinical practice. With a median of 6 cycles (range, 1–8), at least partial response was achieved in 94.6% and at least very good partial response (VGPR) was achieved in 67.8% of patients. Peripheral neuropathy (PN) grade 2–4 was observed in 28.7% of patients. In 72% of patients undergoing stem cell mobilization one apheresis allowed the number of stem cells sufficient for transplantation to be obtained. Following HDT/ASCT the sCR rate increased from 4.9 to 14.4% and CR from 27.8 to 35.6%. The results demonstrated that VTD as an induction regimen was highly efficient in transplant eligible patients with MM with increased at least VGPR rate following prolonged treatment (≥6 cycles). Therapy exhibited no negative impact on stem cell collection, neutrophils and platelets engraftment following ASCT. Therapy was generally well tolerated and PN was the most common reason of dose reduction or treatment discontinuation.
Collapse
Affiliation(s)
- Iwona Hus
- Department of Clinical Transplantology, Medical University of Lublin, 20-081 Lublin, Poland
| | - Joanna Mańko
- Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland
| | - Dariusz Jawniak
- Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland
| | - Artur Jurczyszyn
- Department of Hematology, Collegium Medicum, Jagiellonian University, 30-051 Cracow, Poland
| | - Grzegorz Charliński
- Department of Hematology, Specialist Muncipial Hospital, 87-100 Torun, Poland
| | | | - Lidia Usnarska-Zubkiewicz
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-367 Wroclaw, Poland
| | - Mateusz Sawicki
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-367 Wroclaw, Poland
| | | | - Alina Świderska
- Department of Hematology, University Hospital in Zielona Góra, 65-046 Zielona Góra, Poland
| | - Anna Kopińska
- Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40-032 Katowice, Poland
| | - Norbert Grząśko
- Department of Hematology, St. John of Dukla Lublin Region Cancer Center, 20-090 Lublin, Poland
| | - Małgorzata Raźny
- Department of Hematology, Ludwik Rydygier Memorial Specialized Hospital, 31-826 Cracow, Poland
| | - Aleksandra Wędłowska
- Department of Hematology and Transplantology, Medical University of Gdansk, 80-211 Gdansk, Poland
| | - Aleksander Perzyński
- Department of Hematology, Institute of Hematology and Transfusion Medicine, 00-791 Warsaw, Poland
| | - Aleksandra Gałązka
- Department of Hematology, Institute of Hematology and Transfusion Medicine, 00-791 Warsaw, Poland
| | - Dominik Dytfeld
- Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60-569 Poznan, Poland
| | - Tadeusz Kubicki
- Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60-569 Poznan, Poland
| | - Marek Rodzaj
- Department of Hematology, Ludwik Rydygier Memorial Specialized Hospital, 31-826 Cracow, Poland
| | - Anna Waszczuk-Gajda
- Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland
| | - Joanna Drozd-Sokołowska
- Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland
| | - Bartłomiej Pogłódek
- Department of Oncologic Hematology, Specialist Hospital, 36-200 Brzozów, Poland
| | - Anna Pasternak
- Department of Hematology, Independent Public Health Care of Ministry of The Interior and Administration, 10-228 Olsztyn, Poland
| | - Monika Długosz-Danecka
- Department of Hematology, Collegium Medicum, Jagiellonian University, 30-051 Cracow, Poland
| | - Agnieszka Szymczyk
- Department of Clinical Transplantology, Medical University of Lublin, 20-081 Lublin, Poland
| | - Anna Dmoszyńska
- Department of Clinical Transplantology, Medical University of Lublin, 20-081 Lublin, Poland
| |
Collapse
|
4
|
Mądry K, Lis K, Biecek P, Młynarczyk M, Rytel J, Górka M, Kacprzyk P, Dutka M, Rodzaj M, Bołkun Ł, Krochmalczyk D, Łątka E, Drozd-Sokołowska J, Waszczuk-Gajda A, Knopińska-Posłuszny W, Kopińska A, Subocz E, Masternak A, Guzicka-Kazimierczak R, Gil L, Machowicz R, Biliński J, Giebel S, Czerw T, Dwilewicz-Trojaczek J. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. Clin Lymphoma Myeloma Leuk 2019; 19:264-274.e4. [PMID: 30898482 DOI: 10.1016/j.clml.2019.01.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 01/04/2019] [Accepted: 01/10/2019] [Indexed: 02/07/2023]
Abstract
BACKGROUND Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) patients, including those treated with azacitidine, are at increased risk for serious infections. The aim of our study was to identify patients with higher infectious risk at the beginning of azacitidine treatment. PATIENTS AND METHODS We performed a retrospective evaluation of 298 MDS/CMML/AML patients and included in the analysis 232 patients who completed the first 3 cycles of azacitidine therapy or developed Grade III/IV infection before completing the third cycle. RESULTS Overall, 143 patients (62%) experienced serious infection, and in 94 patients (41%) infection occurred within the first 3 cycles. The following variables were found to have the most significant effect on the infectious risk in multivariate analysis: red blood cell transfusion dependency (odds ratio [OR], 2.38; 97.5% confidence interval [CI], 1.21-4.79), neutropenia <0.8 × 109/L (OR, 3.03; 97.5% CI, 1.66-5.55), platelet count <50 × 109/L (OR, 2.63; 97.5% CI, 1.42-4.76), albumin level <35 g/dL (OR, 2.04; 97.5% CI, 1.01-4.16), and Eastern Cooperative Oncology Group performance status ≥2 (OR, 2.19; 97.5% CI, 1.40-3.54). Each of these variables is assigned 1 point, and the combined score represents the proposed Azacitidine Infection Risk Model. The infection rate in the first 3 cycles of therapy in lower-risk (0-2 score) and higher-risk (3-5 score) patients was 25% and 73%, respectively. The overall survival was significantly reduced in higher-risk patients compared with the lower-risk cohort (8 vs. 29 months). CONCLUSION We selected a subset with high early risk for serious infection and worse clinical outcome among patients treated with azacitidine.
Collapse
Affiliation(s)
- Krzysztof Mądry
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland
| | - Karol Lis
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland.
| | - Przemysław Biecek
- Faculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland
| | - Magda Młynarczyk
- Faculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland
| | - Jagoda Rytel
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland
| | - Michał Górka
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland
| | - Piotr Kacprzyk
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland
| | - Magdalena Dutka
- Department of Hematology and Bone Marrow Transplantation, Medical University, Gdańsk, Poland
| | - Marek Rodzaj
- Department of Hematology, Voivodal Specialistic Hospital, Kraków, Poland
| | - Łukasz Bołkun
- Department of Hematology, Medical University, Białystok, Poland
| | | | - Ewa Łątka
- Department of Hematology, Jagiellonian University, Kraków, Poland
| | - Joanna Drozd-Sokołowska
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland
| | - Anna Waszczuk-Gajda
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland
| | | | - Anna Kopińska
- Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland
| | - Edyta Subocz
- Department of Hematology and Internal Diseases, Military Institute of Medicine, Warsaw, Poland
| | - Anna Masternak
- Department of Hematology, Specialist Hospital, Opole, Poland
| | | | - Lidia Gil
- Department of Hematology, Medical University, Poznań, Poland
| | - Rafał Machowicz
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland
| | - Jarosław Biliński
- Department of Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland
| | - Sebastian Giebel
- Department of Bone Marrow Transplantation and Hematology-Oncology, Cancer Center and Institute of Oncology, Gliwice, Poland
| | - Tomasz Czerw
- Department of Bone Marrow Transplantation and Hematology-Oncology, Cancer Center and Institute of Oncology, Gliwice, Poland
| | | |
Collapse
|
5
|
Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charliński G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Posłuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol 2018; 180:831-839. [PMID: 29315478 DOI: 10.1111/bjh.15092] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2017] [Accepted: 11/08/2017] [Indexed: 12/13/2022]
Abstract
We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age at the time of pPCL diagnosis was 61 years. Ninety-eight patients were treated with novel agents, with an overall response rate of 78%. Fifty-five patients (64%) patients underwent upfront autologous stem cell transplantation (ASCT). The median follow-up time was 50 months (95% confidence interval [CI] 33; 76), with a median overall survival (OS) for the entire group of 23 months (95% CI 15; 34). The median OS time in patients who underwent upfront ASCT was 35 months (95% CI 24·3; 46) as compared to 13 months (95% CI 6·3; 35·8) in patients who did not receive ASCT (P = 0·001). Multivariate analyses identified age ≥60 years, platelet count ≤100 × 109 /l and peripheral blood plasma cell count ≥20 × 109 /l as independent predictors of worse survival. The median OS in patients with 0, 1 or 2-3 of these risk factors was 46, 27 and 12 months, respectively (P < 0·001). Our findings support the use of novel agents and ASCT as frontline treatment in patients with pPCL. The constructed prognostic score should be independently validated.
Collapse
Affiliation(s)
| | - Jakub Radocha
- 4th Department of Medicine - Haematology, Charles University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Julio Davila
- Hospital Universitario de Salamanca, Salamanca, Spain
| | - Mark A Fiala
- Washington University School of Medicine, Saint Louis, MO, USA
| | | | - Norbert Grząśko
- Department of Haematology, St John's Cancer Centre, Lublin, Poland.,Department of Experimental Haematology, Medical University of Lublin, Lublin, Poland
| | - Paweł Robak
- Department of Haematology, Medical University of Lodz, Copernicus Memorial Hospital, Łódź, Poland
| | - Iwona Hus
- Department of Haematology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
| | - Anna Waszczuk-Gajda
- Department of Haematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland
| | | | - Erden Atilla
- Haematology Department and Bone Marrow Transplantation Unit, Ankara University Medical School, Ankara, Turkey
| | | | - Waldemar Sawicki
- Dept. of Internal Medicine and Haematology, Military Institute of Medicine, Warsaw, Poland
| | | | | | - Agoston G Szabo
- Department of Medicine, Section of Haematology, Vejle, Denmark
| | - Roman Hajek
- University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | | | - Agnieszka Kopacz
- Department of Haematology, University of Rzeszów, Rzeszów, Poland
| | - Dorotea Fantl
- Seccion Hematologia Adultos, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Anders Waage
- Norwegian University of Science and Technology, Trondheim, Norway
| | - Irit Avivi
- Tel Aviv Medical Centre, Tel Aviv, Israel
| | - Marek Rodzaj
- Department of Haematology, State Hospital, Cracow, Poland
| | - Xavier Leleu
- Service d'Hematologie CHU, Hopital de la Miletrie, Poitiers, France
| | - Valentine Richez
- Ministry of Interior Hospital in Olsztyn with Warmia and Masuria Oncology Centre, Olsztyn, Poland
| | | | - Anna Masternak
- Department of Haematology, State Hospital, Opole, Poland
| | - Andrew J Yee
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
| | - Agnieszka Barchnicka
- Department of Doctoral Studies, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland
| | | | - Thomas Guerrero-Garcia
- Division of Hematology and Oncology, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, MA, USA
| | - Jieqi Liu
- Rutgers New Jersey Medical School, Newark, NJ, USA
| | - David H Vesole
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA
| | - Jorge J Castillo
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
6
|
Hus I, Manko J, Jawniak D, Jurczyszyn A, Usnarska-Zubkiewicz L, Sawicki M, Charlinski G, Razny M, Rodzaj M, Waszczuk-Gajda A, Drozd-Sokolowska J, Galazka A, Swiderska A, Poglodek B, Pluta A, Druzd-Sitek A, Grzasko N, Kopinska A, Pasternak A, Blonska D, Hus M, Dmoszynska A. HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT - A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- I. Hus
- Clinical Transplantology; Medical University of Lublin; Lublin Poland
| | - J. Manko
- Hematooncology and Bone Marrow Transplantation; Medical University of Lublin; Lublin Poland
| | - D. Jawniak
- Hematooncology and Bone Marrow Transplantation; Medical University of Lublin; Lublin Poland
| | - A. Jurczyszyn
- Department of Hematology, Collegium Medicum; Jagiellonian University; Kraków Poland
| | - L. Usnarska-Zubkiewicz
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation; Wroclaw Medical University; Wroclaw Poland
| | - M. Sawicki
- Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation; Wroclaw Medical University; Wroclaw Poland
| | | | - M. Razny
- Department of Hematology, SS im. Rydygiera; Krakow Poland
| | - M. Rodzaj
- Department of Hematology, SS im. Rydygiera; Krakow Poland
| | - A. Waszczuk-Gajda
- Department of Hematology, Oncology and Internal Medicine; Medical University of Warsaw; Warsaw Poland
| | - J. Drozd-Sokolowska
- Department of Hematology, Oncology and Internal Medicine; Medical University of Warsaw; Warsaw Poland
| | - A. Galazka
- Department of Hematology; Institute of Hematology and Transfusion Medicine; Warsaw Poland
| | - A. Swiderska
- Department of Hematology, WSK; Zielona Gora Poland
| | - B. Poglodek
- Department of Oncologic Hematology, SS; Brzozow Poland
| | - A. Pluta
- Department of Oncologic Hematology, SS; Brzozow Poland
| | - A. Druzd-Sitek
- Department of Lymphoid Malignancies; Institute of Oncology; Warsaw Poland
| | - N. Grzasko
- Department of Hematology; St. John of Dukla Lublin Region Cancer Center; Lublin Poland
| | - A. Kopinska
- Hematooncology and Bone Marrow Transplantation; Medical University of Silesia; Katowice Poland
| | - A. Pasternak
- Department of Hematology, SPZOZ, MSWiA; Olsztyn Poland
| | - D. Blonska
- Department of Hematology; Collegium Medicum UMK; Bydgoszcz Poland
| | - M. Hus
- Hematooncology and Bone Marrow Transplantation; Medical University of Lublin; Lublin Poland
| | - A. Dmoszynska
- Clinical Transplantology; Medical University of Lublin; Lublin Poland
| |
Collapse
|
7
|
Helbig G, Wichary R, Razny M, Rodzaj M, Wozniczka K, Dziaczkowska-Suszek J, Kyrcz-Krzemien S. The proportion of CD3− CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES). Scand J Immunol 2010; 72:372-3. [DOI: 10.1111/j.1365-3083.2010.02436.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
8
|
Rodzaj M, Gałązka K, Majewski M, Zduńczyk A. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase. Pol Arch Intern Med 2009. [DOI: 10.20452/pamw.861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
9
|
Rodzaj M, Gałazka K, Majewski M, Zduńczyk A. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report. Pol Arch Med Wewn 2009; 119:838-841. [PMID: 20010473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Chronic myeloid neoplasm with eosinophilia and abnormalities of platelet-derived growth factor receptor alpha (PDGFRA), referred to until 2008 as chronic eosinophilic leukemia, is distinguished from hypereosinophilic syndrome (HES), if accompanied by genetic abnormalities that enable to determine eosinophil clonality. Typically, HES has a benign course and glucocorticosteroids suffice to achieve remission. In chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA the FIP1L1-PDGFRA fusion gene can be detected. Its product is a protein showing tyrosine kinase activity leading to malignant proliferation of eosinophil precursors. Differential diagnosis of HES is often difficult because hypereosinophilia may also be reactive and may occur in many nonhematological as well as hematological disorders. Thus, reverse-transcription polymerase chain reaction (RT-PCR)is indicated in all patients with HES in order to detect the FIP1L1-PDGFRA transcript. Traditional treatment of chronic myeloid neoplasm with cytostatic drugs results in a short-term and transient remission or stabilization of the disease. We present the case of a 52-year-old patient with chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA, in whom acceleration occurred after a year of cytostatic therapy with hydroxyurea and was successfully treated with imatinib. It was impossible to unequivocally determine the type of bone marrow disease based on histologic criteria, and a wide spectrum of molecular tests differentiating the type of myeloid proliferation were necessary to establish the diagnosis. RT-PCR did not reveal BCR-ABL or JAK2 V617F mutation. Further molecular testing showed rearrangement involving the FIP1L1 gene, thus enabling implementation of targeted therapy.
Collapse
MESH Headings
- Antineoplastic Agents/administration & dosage
- Benzamides
- Disease Progression
- Gene Rearrangement
- Humans
- Hypereosinophilic Syndrome/diagnosis
- Hypereosinophilic Syndrome/drug therapy
- Hypereosinophilic Syndrome/genetics
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Middle Aged
- Oncogene Proteins, Fusion/metabolism
- Piperazines/administration & dosage
- Protein Kinase Inhibitors/administration & dosage
- Pyrimidines/administration & dosage
- Receptor, Platelet-Derived Growth Factor alpha/metabolism
- mRNA Cleavage and Polyadenylation Factors/metabolism
Collapse
Affiliation(s)
- Marek Rodzaj
- Department of Hematology and Internal Diseases, Rydygier Hospital, Kraków, Poland.
| | | | | | | |
Collapse
|
10
|
Rodzaj M, Wilkołek P, Woźniak M, Gajos G. [Angiogenesis and its clinical significance]. Przegl Lek 1996; 53:750-4. [PMID: 9091956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
This study collects past and recent data about neovascularization process and angiogenic factors. Development of the collateral circulation in the heart in response to gradual and progressive coronary artery occlusion was described. Pharmaceutical and surgical methods of angiogenesis induction was discussed. Importance of angiogenic process in many both physiological and pathological situations was noticed. It was pointed out that discovery and cloning of angiogenic cytokines maybe very useful in future treatment.
Collapse
Affiliation(s)
- M Rodzaj
- Kliniki Choroby Wieńcowej Instytutu Kardiologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie
| | | | | | | |
Collapse
|